Aromatase and aromatase inhibitors

Breast Cancer

Volumn 8, Issue 4, 2001, Pages 329-332

  Toi, Masakazu ^a   Bando, Hiroko ^a   Saji, Shigehira ^a  

^a TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

Author keywords

Aromatase; Aromatase inhibitor; Breast cancer; Hormone therapy; Microenvironment

Indexed keywords

ANASTROZOLE; ANDROSTANE DERIVATIVE; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; ENZYME INHIBITOR; EXEMESTANE; LETROZOLE; NITRILE; TRIAZOLE DERIVATIVE;

BREAST TUMOR; COMPARATIVE STUDY; DOSE RESPONSE; DRUG ADMINISTRATION; FEMALE; FOLLOW UP; HUMAN; PATHOLOGY; PHASE 3 CLINICAL TRIAL; REVIEW; SURVIVAL; TREATMENT OUTCOME;

ANDROSTADIENES; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS, PHASE III; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; ENZYME INHIBITORS; FEMALE; FOLLOW-UP STUDIES; HUMANS; NITRILES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TRIAZOLES;

EID: 0035751597     PISSN: 13406868     EISSN: 18804233     Source Type: Journal    
DOI: 10.1007/BF02967533     Document Type: Conference Paper

References (11)

1. Miller WR: Aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treat Rev 16:83-93, 1989. (Pubitemid 19225852)
2. Kirma N, Gill K, Mandava U, et al: Overexpression of aromatase leads to hyperplasia and changes in the expression of genes involved in apoptosis, cell cycle, growth, and tumor suppressor functions in the mammary glands of transgenic mice. Cancer Res 61:1910-1918, 2001. (Pubitemid 32692007)
3. Zhou J, Curates B, Yang S, et al: Malignant breast epithelial cells stimulate aromatase expression via promoter II in human adipose fibroblasts: an epithelialstromal interaction in breast tumors mediated by CCAAT/enhancer binding protein beta. Cancer Res 61:2328-2334, 2001. (Pubitemid 32692067)
4. Lonning PE: Aromatase inhibitors and their future role in post-menopausal women with early breast cancer. Br J Cancer 78:12-15, 1998.
5. Mouridsen H, Gershanovich M, Sun Y, et al: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 19:2596-2606, 2001. (Pubitemid 32451796)
6. Nabholtz JM, Buzdar A, Pollak M, et al: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18:3758-3767, 2000.
7. Bonneterre J, Thurlimann B, Robertson JF, et al: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18:3748-3757, 2000.
8. Lonning PE, Bajetta E, Murray R, et al: Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 18:2234-2244, 2000. (Pubitemid 30350215)
9. Dowsett M, Jones A, Johnston SR, et al: In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1:1511-1515, 1995. (Pubitemid 26028086)
10. Dixon JM, Renshaw L, Bellamy C, et al: The effects of neoadjuvant anastrozole (Arimidex) on tumor volume in postmenopausal women with breast cancer: a randomized, double-blind, single-center study. Clin Cancer Res 6:2229-35, 2000. (Pubitemid 30399188)
11. Howell A, Anderson E, Blarney R, et al: The primary use of endocrine therapies.